Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to buy right now. Geron Corporation (NASDAQ:GERN) reported its fiscal Q2 2025 results on August 6, announcing $49.0 million in RYTELO net product revenue in the quarter.
Management also reported that the Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and is anticipated to be fully enrolled by year-end.
On August 15, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Geron Corporation, keeping the associated price target the same at $3.00.
In another report released on August 7, Barclays also maintained a Buy rating on Geron Corporation with a $4.00 price target.
The stock’s median price target of $1.43 implies an upside of 179.72% from current levels.
Geron Corporation is a biotechnology company that develops Imetelstat, a telomerase inhibitor in hematologic myeloid malignancies. It focuses on oncology-focused therapeutic products.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
